🇺🇸 Fentanyl-TTS in United States
33 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 33
Most-reported reactions
- Nausea — 5 reports (15.15%)
- Dizziness — 4 reports (12.12%)
- General Physical Health Deterioration — 4 reports (12.12%)
- Altered State Of Consciousness — 3 reports (9.09%)
- Anaemia — 3 reports (9.09%)
- Drug Dependence — 3 reports (9.09%)
- Drug Interaction — 3 reports (9.09%)
- Pneumonia — 3 reports (9.09%)
- Vomiting — 3 reports (9.09%)
- Blood Urine Present — 2 reports (6.06%)
Other Pain Management approved in United States
Frequently asked questions
Is Fentanyl-TTS approved in United States?
Fentanyl-TTS does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Fentanyl-TTS in United States?
Janssen-Cilag, S.A. is the originator. The local marketing authorisation holder may differ — check the official source linked above.